The pharmacogenomics of warfarin safety and effectiveness in children
Use of the anticoagulant warfarin for thromboembolic disease prophylaxis is limited by a large inter - patient dose variability and high risk of adverse drug reactions (ADRs). Polymorphisms in two genes , CYP2C9 and VK ORC1 , have consistently been shown to be associated with warfar in dose requirem...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2013
|
| Online Access: | http://hdl.handle.net/2429/44242 |